The goal of the Biostatistics Core is to provide quantitative support for all projects, pilot projects and clinical trials associated with the University of Colorado lung Cancer SPORE program. Specifically, the Biostatistics Core: 1) provides advice on the design of laboratory, animal and clinical studies; 2) assists with the implementation of these studies, particularly with respect to the design of forms and databases and the logistics of data collection and entry; 3) assists with the evaluation of study results including analysis, display and interpretation; 4) assists in the preparation of final study reports and; 5) provides surveillance for quality Assurance with respect to the conduct of laboratory, animal and clinical studies. During the past 2 1/2 years, 15 clinical trials have been written. Of these, three are completed, 9 are active, and 6 are pending activation. Over 1,000 patients and subjects have been enrolled onto these trials. The Biostatistics Core was involved in the design, implementation and analysis of all of these trials. The clinical, pathologic and laboratory data are all entered into a Paradox database which is available to all SPORE investigators. The Biostatistics Core will continue to provide quantitative consultation for the five years of the SPORE grant renewal. Through personnel with appointments in the Department of Preventive Medicine and Biometrics, SPORE investigators will also have access as need to professionals with expertise is many quantitative areas without additional charge.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058187-07
Application #
6102829
Study Section
Project Start
1999-05-01
Project End
2000-04-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Geraci, Mark W (2018) TARGETING THE PROSTACYCLIN/PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AXIS IN LUNG CANCER CHEMOPREVENTION. Trans Am Clin Climatol Assoc 129:48-55
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Kimball, Abigail K; Oko, Lauren M; Bullock, Bonnie L et al. (2018) A Beginner's Guide to Analyzing and Visualizing Mass Cytometry Data. J Immunol 200:3-22
Tippimanchai, Darinee D; Nolan, Kyle; Poczobutt, Joanna et al. (2018) Adenoviral vectors transduce alveolar macrophages in lung cancer models. Oncoimmunology 7:e1438105
DeHart, David N; Lemasters, John J; Maldonado, Eduardo N (2018) Erastin-Like Anti-Warburg Agents Prevent Mitochondrial Depolarization Induced by Free Tubulin and Decrease Lactate Formation in Cancer Cells. SLAS Discov 23:23-33
Ren, Shengxiang; Zhang, Shucai; Jiang, Tao et al. (2018) Early detection of lung cancer by using an autoantibody panel in Chinese population. Oncoimmunology 7:e1384108
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Iams, Wade T; Yu, Hui; Shyr, Yu et al. (2018) First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. Clin Lung Cancer 19:531-543
McDaniel, Nellie K; Cummings, Christopher T; Iida, Mari et al. (2018) MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. Mol Cancer Ther 17:2297-2308
Ghosh, Moumita; Miller, York E; Vandivier, R William et al. (2018) Reply to Sohal: Airway Basal Cell Reprogramming and Epithelial-Mesenchymal Transition: A Potential Key to Understanding Early Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 197:1645-1646

Showing the most recent 10 out of 435 publications